Effect of dapagliflozin on uric acid in patients with chronic heart failure and hyperuricemia

Table 1 Baseline characteristics of participants, n (%)/ mean ± SD

Variable	Age (yr)	Sex (male)	LVEF (%)	NYHA class	Comorbidities	Medications	Serum uric acid (mg/dL)	eGFR (mL/min/1.73 m2)
Dapagliflozin group (n = 100)	62.3 ± 9.8	68	32.5 ± 6.7	II: 36; III: 52; IV: 12	Diabetes: 42; hypertension: 76; coronary artery disease: 54; renal impairment: 28	ACEI/ARB: 92; β-blocker: 88; MRA: 72; Diuretic: 80	7.5 ± 1.2	60.4 ± 15.8
Placebo group (n = 100)	63.1 ± 10.2	66	33.2 ± 7.1	II: 38; III: 50; IV: 12	Diabetes: 40; hypertension: 78; coronary artery disease: 56; renal impairment: 30	ACEI/ARB: 90; β-blocker: 86; MRA: 70; diuretic: 82	7.6 ± 1.3	59.8 ± 16.2
P value	0.56	0.81	0.47	0.73	0.83; 0.77; 0.81; 0.79	0.67; 0.73; 0.79; 0.77	0.62	0.74

LVEF: Left ventricular ejection fraction; NYHA: New York heart association; eGFR: Estimated glomerular filtration rate; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; MRA: Mineralocorticoid receptor antagonist.